Q30 – 68: Product Analysis (All Products)

*Reporting Multiple Instances of Product Analysis
To report multiple instances of product analysis, complete questions 30-68 by adding additional instances in FormsNet3SM

Question 30: Specify the timepoint in the product preparation phase that the product was analyzed

Report the time in the product preparation phase the product was analyzed. A maximum of three timepoints may be reported. Each timepoint can only be reported once.

• Fresh manipulated product: Assessment of a fresh manipulated product. This will usually be performed at the manufacturing / processing site
• Prior to cryopreservation of manipulated product plus additives: Assessment of a fresh manipulated product, plus additives. This will usually be performed at the manufacturing / processing site
• Post-thaw of cryopreserved manipulated product: Assessment of the cryopreserved, manipulated product after thawing. This will usually be performed at the transplant center prior to infusion of the product

Question 31: Date of product analysis

Report the date when the product was analyzed for each timepoint reported. The date of product analysis is not necessarily the date of the product infusion.

Question 32: Total volume of product plus additives

Enter the total volume of the product plus additives in the bag(s) for the reported timepoint. Report the volume in milliters (mL).

Questions 33 – 34: CD34+ cells

Indicate if the CD34+ cells were quantified at the reported timepoint. If Done, report the absolute number of CD34+ cells for the specified timepoint. Do not report cells per kilogram. If the CD34+ cells were not quantified for the specific timepoint, select Not done and continue with question 39

*CD34+ and TNC Viability
The anticipated viability will only be done on CD34+ cells; however, the TNC viability may be reported if CD34+ viability was not performed. If both the CD34+ and TNC viability were performed, report the CD34+ viability . If neither the CD34+ and TNC viability was performed, report Not done.

*CD34+ Viability
If viability was performed on the entire product or select cells (i.e. viability was performed on both the CD34+ and CD3+ cells) and not on the CD34+ cells alone, report Not done for the CD34+ viability.

Questions 35 – 36: Viability of CD34+ cells

If the viability of the CD34+ cells was quantified, select Done and report the percentage of viable cells. If the viability was Not done, continue with question 39.

Select Unknown if there is no documentation to confirm if viability was performed.

If the laboratory assay only measures CD34+ viable cells, report the number of viable CD34+ cells in question 34, select Done for question 35, and report a viability of 100% in question 36.

Questions 37 – 38: Method of testing CD34+ cell viability

Indicate the method of testing viability

• Flow cytometry based: 7-AAD (7-aminoactinomycin D) and propidium iodide are compounds that can stain dead cells but will not cross the membrane of living cells. Cytometric techniques are used to calculate the percentage of viable cells in a sample.
• Trypan blue: a technique where the dead cells become stained when in contact with the compound, but living cells remain impermeable to the dye. Cells are counted under a microscope to determine the percentage of viable cells in a sample.
• Other method: If the cell viability was tested using a different method, select this option and specify the method in question 38.

Questions 39 – 40: Other cell type

Indicate if an “other” cell type was quantified at the reported timepoint. If Done, report the total number of “other” cell types tested. The maximum number of cell types that can be reported is four. The number of cell types reported will enable the appropriate number of instances (questions 41 – 64) in FormsNet3SM.

If no “other” cell types were quantified at the reported timepoint, select Not done and continue with question 65.

Questions 41 – 64: Specify other cell types

For each cell type, a separate instance will be enabled. Specify the “other” cell type quantified at the reported timepoint and report the absolute number of cells. Do not report cells per kilogram.

Additionally, indicate if the viability if the “other” cells were quantified. If Done, report the viability percent of cells and specify the method of testing for viability. Select Unknown if there is no documentation to confirm if viability was performed. For commercial products, the viability will be performed at the manufacturing site and this information may or may not be reported to the transplant center.

• Flow cytometry based: 7-AAD (7-aminoactinomycin D) and Propidium iodide are compounds that can stain dead cells but will not cross the membrane of living cells. Cytometric techniques are used to calculate the percentage of viable cells in a sample.
• Trypan blue: a technique where the dead cells become stained when in contact with the compound, but living cells remain impermeable to the dye. Cells are counted under a microscope to determine the percentage of viable cells in a sample.
• Other method: If the cell viability was tested using a different method, select this option and specify the method.

Select Unknown if there is no documentation to confirm if viability was performed. For commercial products, the viability will be performed at the manufacturing site and this information may or may not be reported to the transplant center.

*Vector copy number (VCN)
The VCN for the infused product is only enabled if Ex vivo transduction is reported as a genetic manipulation.

Questions 65 – 66: Vector copy number (VCN) in the infused product

A vector copy number (VCN) is the number of vector copies per diploid genome. This information may be available from a clinical study protocol or information that comes with the product. Indicate if the VCN of the infused product is Known or Unknown. If Known, report the VCN. If Unknown, continue with question 67.

*Percentage of gene edited cells
The percentage of gene edited cells for the infused product is only enabled if Gene editing is reported as a genetic manipulation.

Questions 67 – 68: Percentage of gene edited cells in the infused product

When product is genetically modified by gene editing, the percentage of gene edited cells maybe be known. This information may be available from a clinical study protocol or information that comes with the product. Indicate if the percentage of gene edited cells in the infused product is Known or Unknown. If Known, report the percentage of gene edited cells. If Unknown, continue with question 69.

Section Updates:

Question Number	Date of Change	Add/Remove/Modify	Description	Reasoning (If applicable)
.	.	.	.	.

Copyright © 2004-2024 The Medical College of Wisconsin, Inc. and NMDP. All Rights Reserved.
CIBMTR® (Center for International Blood and Marrow Transplant Research) is a research collaboration between the Medical College of Wisconsin and NMDP.